Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
29.73
+0.37 (1.26%)
At close: Nov 12, 2024, 4:00 PM
29.81
+0.08 (0.26%)
After-hours: Nov 12, 2024, 6:33 PM EST
Guardant Health Revenue
Guardant Health had revenue of $191.48M in the quarter ending September 30, 2024, with 33.87% growth. This brings the company's revenue in the last twelve months to $692.26M, up 29.20% year-over-year. In the year 2023, Guardant Health had annual revenue of $563.95M with 25.45% growth.
Revenue (ttm)
$692.26M
Revenue Growth
+29.20%
P/S Ratio
5.15
Revenue / Employee
$389,126
Employees
1,779
Market Cap
3.67B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bausch Health Companies | 9.47B |
Perrigo Company | 4.39B |
DENTSPLY SIRONA | 3.90B |
Envista Holdings | 2.50B |
Neogen | 912.20M |
PTC Therapeutics | 900.66M |
Apellis Pharmaceuticals | 715.22M |
Axonics | 431.90M |
GH News
- 5 days ago - Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance - Business Wire
- 11 days ago - Guardant Health to Participate in Upcoming Investor Conferences - Business Wire
- 13 days ago - Guardant Health Named to TIME's List of the Best Inventions of 2024 - Business Wire
- 15 days ago - Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024 - Business Wire
- 19 days ago - Roberto A. Mignone Joins Guardant Health Board of Directors - Business Wire
- 4 weeks ago - Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 - Business Wire
- 7 weeks ago - GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long - Business Wire